한국어
English
日本語
中文(简体)
Ninlaro Capsule 2.3 milligrams (Ixazomib Citrate)
3.29mg
Hard capsule · Prescription medication
Takeda Korea Pharmaceutical Co., Ltd.
Ixazomib citrate is an active ingredient used in the treatment of multiple myeloma.
MFDS ingredient code M266478
Ixazomib citrate belongs to a class of anticancer agents that inhibit proteasomes. It is primarily used to treat hematologic cancers such as multiple myeloma and is intended to disrupt the growth and survival of cancer cells.
Ixazomib citrate blocks the activity of proteasomes within cancer cells, preventing unnecessary proteins from being broken down. As a result, proteins accumulate within the cancer cells, leading to cellular dysfunction and ultimately the death of the cancer cells.
Approved uses differ by product. Check each product's information for its actual use.
Ixazomib citrate is an oral proteasome inhibitor, and unlike other proteasome inhibitors that are administered via injection, it can be taken in pill form. This feature enhances the convenience of treatment and contributes to improving the quality of life for patients.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
3 total
3.29mg
Hard capsule · Prescription medication
Takeda Korea Pharmaceutical Co., Ltd.
4.3mg
Hard capsule · Prescription medication
Takeda Korea Pharmaceutical Co., Ltd.
5.7mg
Hard capsule · Prescription medication
Takeda Pharmaceuticals Korea Co., Ltd.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.